沙利度胺聯合地塞米松治療多發性骨髓瘤的臨床分析_《華西醫學》

作者：

1洛陽市中心醫院血液科,河南洛陽 471000; 2 四川省人民醫院血液科,四川成都 610072;

關鍵詞：

沙利度胺地塞米松多發性骨髓瘤

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的:觀察沙利度胺聯合地塞米松(TD)治療初治多發性骨髓瘤(MM)的療效和毒副反應。方法:25例初治MM患者,給予沙利度胺(100mg/d起,每周增加50mg~100mg/d到200mg/d)聯合地塞米松40mg/d(d1~4,9~12,17~20),28天為一療程,至少2個療程。與既往18例使用VAD方案治療MM初治患者作對照。結果:觀察組25例中,14例部分緩解(56％),6例進步(24％),總有效率80%。對照組18例中,部分緩解13例,進步2例,總有效率83.3%。兩組總有效率無顯著性差異(P gt;0.05),但主要副作用發生率觀察組明顯少于對照組(P lt;0.05)。結論:沙利度胺聯合地塞米松(TD)治療多發性骨髓瘤療效高、副作用少和耐受性好,值得進一步的臨床觀察和推廣。老年患者(年齡 gt;65歲),地塞米松減量應用,可減少副作用,且不影響療效的發揮。

引用本文： 李波,張晉琳,甘茂周,王曉冬,王春森,祝彪. 沙利度胺聯合地塞米松治療多發性骨髓瘤的臨床分析. 華西醫學, 2009, 24(7): 1736-1739. doi: 復制

1.	RICHARDSON P, SCHLOSSMAN R, JAGANNATH SRICHARDSON P, et al. Thalidomide for patients with relapse multiple myeloma after highdose chemotherapy and stem cell transplantation:results of an openlabel multicenter phase 2 studies of efficacy, toxicity, and biological activity [J]. Mayo Clin Proc, 2004, 79:875-882.
2.	BERNARDESCHI P, DENTICO P, ROSSI S, et al. Chemoresistant myeloma:phase II clinical study with lowdose thalidomide plus highdose dexamethasone [J]. Chemother 2004, 16 (suppl 5):90-93.
3.	RAJKUMAR S V, BLOOD E, VESOLE D, et al. Phase III trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma:a clinical trial coordinated by the Eastern Cooperative Oncology Group [J]. Clin Oncol, 2006, 24:431-436.
4.	張之南,主編.血液病診斷及療效標準[M]. 第2版.北京:科技出版社,1998:373-380.
5.	孫燕,周際昌,主編.臨床腫瘤內科手冊[M].第4版.北京:人民衛生出版社,2003:102-104.
6.	ALEXANIAN R, DIMOPOULOS M A, DELASALLE K, et al. Primary dexamethasone treatment of multiple myeloma [J]. Blood, 1992, 80:887-890.
7.	JIMENEZZEPEDA, DOMINGUEZMARTINEZ. Vincristine, doxorubicin, and dexamethasone or thalidomide plus dexamethasone for newly diagnosed patients with multiple myeloma? [J]. Eur J haematol, 2006, 77:239-244.
8.	朱興虎,魏旭東,高全立,等.沙利度胺聯合地塞米松治療初發性多發性骨髓瘤的臨床觀察.白血病[J].淋巴瘤,2006,15(1):48-49.
9.	RAJKUMAR S V, JACOBUS S, CALLANDER N, et al. a randomized trial of lenaldomide plus highdose dexamethasone (rd) versus lenalidomide plus lowdose dexamethasone (RD) in newly diagnosed multiple myeloma (E4A03):a trial coordinated by the Eastern Cooperative Oncology Group[J].Blood,2007,110:31a.abstract 74.

1. RICHARDSON P, SCHLOSSMAN R, JAGANNATH SRICHARDSON P, et al. Thalidomide for patients with relapse multiple myeloma after highdose chemotherapy and stem cell transplantation:results of an openlabel multicenter phase 2 studies of efficacy, toxicity, and biological activity [J]. Mayo Clin Proc, 2004, 79:875-882.
2. BERNARDESCHI P, DENTICO P, ROSSI S, et al. Chemoresistant myeloma:phase II clinical study with lowdose thalidomide plus highdose dexamethasone [J]. Chemother 2004, 16 (suppl 5):90-93.
3. RAJKUMAR S V, BLOOD E, VESOLE D, et al. Phase III trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma:a clinical trial coordinated by the Eastern Cooperative Oncology Group [J]. Clin Oncol, 2006, 24:431-436.
4. 張之南,主編.血液病診斷及療效標準[M]. 第2版.北京:科技出版社,1998:373-380.
5. 孫燕,周際昌,主編.臨床腫瘤內科手冊[M].第4版.北京:人民衛生出版社,2003:102-104.
6. ALEXANIAN R, DIMOPOULOS M A, DELASALLE K, et al. Primary dexamethasone treatment of multiple myeloma [J]. Blood, 1992, 80:887-890.
7. JIMENEZZEPEDA, DOMINGUEZMARTINEZ. Vincristine, doxorubicin, and dexamethasone or thalidomide plus dexamethasone for newly diagnosed patients with multiple myeloma? [J]. Eur J haematol, 2006, 77:239-244.
8. 朱興虎,魏旭東,高全立,等.沙利度胺聯合地塞米松治療初發性多發性骨髓瘤的臨床觀察.白血病[J].淋巴瘤,2006,15(1):48-49.
9. RAJKUMAR S V, JACOBUS S, CALLANDER N, et al. a randomized trial of lenaldomide plus highdose dexamethasone (rd) versus lenalidomide plus lowdose dexamethasone (RD) in newly diagnosed multiple myeloma (E4A03):a trial coordinated by the Eastern Cooperative Oncology Group[J].Blood,2007,110:31a.abstract 74.

《華西醫學》

沙利度胺聯合地塞米松治療多發性骨髓瘤的臨床分析

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《華西醫學》

沙利度胺聯合地塞米松治療多發性骨髓瘤的臨床分析

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料